NYSE - Nasdaq Real Time Price USD
Eli Lilly and Company (LLY)
As of 11:20 AM EDT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 15 | 10 | 23 |
| Avg. Estimate | 1.4 | 5.43 | 13.35 | 23.1 |
| Low Estimate | 1.17 | 4.6 | 12.97 | 18.6 |
| High Estimate | 1.86 | 6.01 | 14.28 | 29.8 |
| Year Ago EPS | 0.1 | 2.49 | 6.32 | 13.35 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 13 | 25 | 25 |
| Avg. Estimate | 12.18B | 13.96B | 46.24B | 58.38B |
| Low Estimate | 11.63B | 13.21B | 45.4B | 52.68B |
| High Estimate | 12.66B | 14.46B | 47.35B | 67.17B |
| Year Ago Sales | 9.5B | 9.35B | 34.12B | 46.24B |
| Sales Growth (year/est) | 28.20% | 49.20% | 35.50% | 26.30% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.13 | 2.22 | 2.46 | 2.6 |
| EPS Actual | 0.1 | 2.49 | 2.58 | 3.92 |
| Difference | 0.23 | 0.27 | 0.12 | 1.32 |
| Surprise % | 176.90% | 12.20% | 4.90% | 50.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.4 | 5.43 | 13.35 | 23.1 |
| 7 Days Ago | 3.63 | 5.42 | 15.83 | 23.05 |
| 30 Days Ago | 4.48 | 5.41 | 16.41 | 23.02 |
| 60 Days Ago | 4.47 | 5.31 | 16.44 | 22.45 |
| 90 Days Ago | 3.8 | 4.62 | 13.75 | 19.37 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 2 | 1 | 4 |
| Up Last 30 Days | -- | 5 | 2 | 7 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 6 | 2 | 6 | -- |
Growth Estimates
| CURRENCY IN USD | LLY | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 1,300.00% | -- | -- | 4.10% |
| Next Qtr. | 118.10% | -- | -- | 7.60% |
| Current Year | 111.20% | -- | -- | 2.50% |
| Next Year | 73.00% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 72.95% | -- | -- | 11.89% |
| Past 5 Years (per annum) | -1.53% | -- | -- | -- |
Top Analysts Yahoo Finance’s Top Analysts section provides an objective scorecard to evaluate the accuracy of Wall Street analyst ratings and price targets.
Learn More
Yahoo Finance’s Top Analysts section provides an objective scorecard to evaluate the accuracy of Wall Street analyst ratings and price targets.
Learn MoreAnalyst | Overall Score | Direction Score | Price Score | Latest Rating | Price Target | Date |
|---|---|---|---|---|---|---|
| Cantor Fitzgerald | 82 | 89 | 99 | Overweight | 885 | 9/16/2024 |
| Truist Securities | 82 | 87 | 99 | Buy | 1033 | 10/11/2024 |
| Wells Fargo | 72 | 65 | 99 | Overweight | 1000 | 8/9/2024 |
| JP Morgan | 67 | 71 | 85 | Overweight | 1100 | 9/13/2024 |
| Morgan Stanley | 66 | 71 | 81 | Overweight | 1106 | 8/28/2024 |
| Citigroup | 64 | 71 | 69 | Buy | 1060 | 9/14/2024 |
| Guggenheim | 60 | 65 | 71 | Buy | 1030 | 8/16/2024 |
| Barclays | 59 | 57 | 100 | Overweight | 1025 | 7/11/2024 |
| B of A Securities | 54 | 54 | 79 | Buy | 1125 | 8/10/2024 |
| BMO Capital | 53 | 45 | 96 | Outperform | 1101 | 8/10/2024 |
Rows per page
1-10 of 16
Upgrades & Downgrades
| Maintains | Truist Securities: Buy to Buy | 10/10/2024 |
| Reiterates | Deutsche Bank: Buy to Buy | 10/3/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/16/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 9/13/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/9/2024 |
| Reiterates | Morgan Stanley: Overweight to Overweight | 8/27/2024 |
Related Tickers
JNJ Johnson & Johnson
164.14
-0.09%
PFE Pfizer Inc.
29.29
-1.30%
ABBV AbbVie Inc.
189.55
-0.48%
MRK Merck & Co., Inc.
109.57
-0.77%
AMGN Amgen Inc.
321.54
-0.03%
BMY Bristol-Myers Squibb Company
52.90
-0.89%
GILD Gilead Sciences, Inc.
87.32
+0.66%
AZN AstraZeneca PLC
78.11
-0.26%
GSK GSK plc
39.01
-0.51%
NVS Novartis AG
116.49
-0.07%